Company Encyclopedia
View More
name
Alterity Therapeutics
ATHE.US
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
1.946 T
ATHE.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking144/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-43.23%E
    • Profit Margin-223.35%E
    • Gross Margin97.66%A
  • Growth ScoreA
    • Revenue YoY32.47%A
    • Net Profit YoY37.81%B
    • Total Assets YoY134.21%A
    • Net Assets YoY200.61%A
  • Cash ScoreC
    • Cash Flow Margin-44.77%D
    • OCF YoY32.47%A
  • Operating ScoreD
    • Turnover0.17D
  • Debt ScoreA
    • Gearing Ratio7.87%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alterity Therapeutics Appoints Julian Babarczy as Director

    Julian Babarczy has been appointed as a director of Alterity Therapeutics Ltd., effective 21 November 2025.

    Reuters·
    US
    ATHE
    -1.55%
    Reuters·
    US
    ATHE
    -1.55%

    Alterity Therapeutics Announces New Director Appointment and Securities Interests

    Alterity Therapeutics has appointed David Stamler as a director, effective November 21, 2025, and disclosed his securities interests, including shares and options. This appointment may impact the company's governance and strategic direction, highlighting its commitment to strengthening leadership. Alterity Therapeutics focuses on developing therapies for neurodegenerative diseases.

    Tip Ranks·
    US
    ATHE
    -1.55%
    Tip Ranks·
    US
    ATHE
    -1.55%

    Alterity Therapeutics Announces Director Departure

    Alterity Therapeutics announced the departure of Geoffrey Kempler as a director effective November 21, 2025. Kempler's exit, given his significant holdings, may impact the company's strategic direction and investor confidence. Alterity focuses on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. The company's current market cap is A$97.88M, with a strong sell technical sentiment signal.

    Tip Ranks·
    US
    ATHE
    -1.55%
    Tip Ranks·
    US
    ATHE
    -1.55%

    Alterity Therapeutics Held Annual General Meeting

    Alterity Therapeutics Ltd. held its Annual General Meeting on November 21, 2025, where shareholders approved the re-election of board members and the appointment of the auditor. This information was published via EDGAR by Alterity Therapeutics Ltd.

    Reuters·
    US
    ATHE
    -1.55%
    Reuters·
    US
    ATHE
    -1.55%

    Alterity Therapeutics Announces Board Reshuffle as Chairman and Director Retire

    Alterity Therapeutics Ltd. announced board changes with the retirement of Geoffrey Kempler, founding shareholder and Non-Executive Chairman, and Brian Meltzer, Non-Executive Director, ahead of its Annual General Meeting on November 21, 2025. These changes aim to support the company's growth as it moves towards Phase 3 clinical development.

    Reuters·
    US
    ATHE
    -1.55%
    Reuters·
    US
    ATHE
    -1.55%
    © 2025 Longbridge｜Disclaimer